Grillo T, Silveira C, Quaglio A, de Medeiros Dutra R, Baima J, Bazan S
World J Cardiol. 2023; 15(5):217-228.
PMID: 37274378
PMC: 10237008.
DOI: 10.4330/wjc.v15.i5.217.
Yilmaz N, Karadag O, Kimyon G, Yazici A, Yilmaz S, Kalyoncu U
Eur J Rheumatol. 2016; 1(2):51-54.
PMID: 27708874
PMC: 5042277.
DOI: 10.5152/eurjrheumatol.2014.018.
Lopez-Serrano P, de la Fuente Briongos E, Carrera Alonso E, Perez-Calle J, Fernandez Rodriguez C
World J Hepatol. 2015; 7(3):539-47.
PMID: 25848477
PMC: 4381176.
DOI: 10.4254/wjh.v7.i3.539.
Huang C, Yu T, de la Monte S, Wands J, Derdak Z, Kim M
J Hepatol. 2015; 63(1):191-8.
PMID: 25724365
PMC: 4475483.
DOI: 10.1016/j.jhep.2015.02.030.
Xuan D, Yu Y, Shao L, Wang J, Zhang W, Zou H
Clin Rheumatol. 2013; 33(4):577-86.
PMID: 24343455
PMC: 3962582.
DOI: 10.1007/s10067-013-2450-9.
Deterioration of the liver biochemistry due to reactivation of chronic hepatitis B during etanercept treatment for rheumatoid arthritis.
Kuo S, Lee H, Chen W, Chou C, Tsai C
BMJ Case Rep. 2011; 2009.
PMID: 21686590
PMC: 3029840.
DOI: 10.1136/bcr.09.2008.0873.
Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.
Liu C, Chen P, Chen D, Kao J
Hepatol Int. 2011; 7(2):316-26.
PMID: 21670970
DOI: 10.1007/s12072-011-9279-6.
Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy.
Manzano-Alonso M, Castellano-Tortajada G
World J Gastroenterol. 2011; 17(12):1531-7.
PMID: 21472116
PMC: 3070121.
DOI: 10.3748/wjg.v17.i12.1531.
[Infectious complications of biologic therapy in patients with rheumatoid arthritis].
Meyer-Olson D, Hoeper K, Schmidt R
Z Rheumatol. 2010; 69(10):879-88.
PMID: 21128049
DOI: 10.1007/s00393-010-0677-2.
A practical approach to monitoring patients on biological agents for the treatment of psoriasis.
Emer J, Frankel A, Zeichner J
J Clin Aesthet Dermatol. 2010; 3(8):20-6.
PMID: 20877538
PMC: 2945861.
Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.
Carroll M, Forgione M
Clin Rheumatol. 2010; 29(9):1021-9.
PMID: 20556450
DOI: 10.1007/s10067-010-1523-2.
Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis.
Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y
Clin Rheumatol. 2010; 32 Suppl 1:S47-9.
PMID: 20379839
PMC: 3594820.
DOI: 10.1007/s10067-010-1438-y.
Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?.
Yazdany J, Calabrese L
Arthritis Care Res (Hoboken). 2010; 62(5):585-9.
PMID: 20191573
PMC: 2924189.
DOI: 10.1002/acr.20167.
Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.
Charpin C, Guis S, Colson P, Borentain P, Mattei J, Alcaraz P
Arthritis Res Ther. 2009; 11(6):R179.
PMID: 19941642
PMC: 3003507.
DOI: 10.1186/ar2868.
Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept.
Carlsen K, Riis L, Madsen O
Clin Rheumatol. 2009; 28(8):1001-3.
PMID: 19370307
DOI: 10.1007/s10067-009-1179-y.
Hepatitis C virus and inflammatory bowel disease.
Horn T, Reynolds J, de Villiers W, Pena L
Dig Dis Sci. 2008; 54(6):1171-7.
PMID: 18975088
DOI: 10.1007/s10620-008-0489-2.
Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab.
Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H
J Gastroenterol. 2008; 43(5):397-401.
PMID: 18592158
DOI: 10.1007/s00535-008-2165-x.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Furst D, Breedveld F, Kalden J, Smolen J, Burmester G, Sieper J
Ann Rheum Dis. 2007; 66 Suppl 3:iii2-22.
PMID: 17934088
PMC: 2095281.
DOI: 10.1136/ard.2007.081430.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
Furst D, Breedveld F, Kalden J, Smolen J, Burmester G, Emery P
Ann Rheum Dis. 2006; 65 Suppl 3:iii2-15.
PMID: 17038465
PMC: 1798383.
DOI: 10.1136/ard.2006.061937.
Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection.
Sakellariou G, Chatzigiannis I
Clin Rheumatol. 2006; 26(6):950-2.
PMID: 16865308
DOI: 10.1007/s10067-006-0392-1.
